Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many statements are not supported by the provided label excerpts and several include mechanisms/quantifications or recommendations not shown in the supplied prescribing information. Some label-supported items (e.g., >3x ULN incidence 0.7%, liver enzyme testing prior to and at 12 weeks, and contraindication in active liver disease) are present.
Category Scores
Accurate Statements
Elevations of liver enzymes above three times the upper limit of normal occur in about 0.7 percent of users.
Label 5 WARNINGS AND PRECAUTIONS (Liver Dysfunction): “Persistent elevations (>3 times the upper limit of normal [ULN])… occurred in 0.7% of patients who received LIPITOR in clinical trials…”
Prescribing information cautions against use in active liver disease.
Label 4 CONTRAINDICATIONS: “Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.”
The label includes warnings about liver enzyme monitoring and cautions against use in active liver disease.
Label 5 WARNINGS AND PRECAUTIONS (Liver Dysfunction): “Liver function tests be performed prior to and at 12 weeks following both the initiation…” plus Label 4 CONTRAINDICATIONS (Active liver disease).
Prescribing information lists liver enzyme monitoring recommendations for Lipitor.
Label 5 WARNINGS AND PRECAUTIONS (Liver Dysfunction): “Liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose…”
Unsupported Statements
These liver enzyme changes usually reverse when treatment stops.
No statement in the provided label excerpts describes reversibility upon discontinuation of LIPITOR.
Rare cases of liver injury, including hepatitis and failure, occur with atorvastatin.
Provided label excerpts do not mention hepatitis or liver failure as rare cases.
FDA data track voluntary reports of liver injury events with atorvastatin.
Provided label excerpts do not reference FDA voluntary report data.
Actual rates of serious liver reactions remain low.
No quantitative or qualitative “serious liver reactions” rate is provided in the supplied excerpts.
Liver injury events often occur in patients who already have liver disease or take other hepatotoxic drugs.
Provided excerpts do not describe frequency/pattern of liver injury events by baseline liver disease or concomitant hepatotoxic drugs.
Doctors usually check liver function before prescribing Lipitor.
The label excerpt indicates liver function tests prior to initiation, but the specific claim attributes this to “Doctors usually check” (practice pattern) rather than the label recommendation itself.
Doctors check liver function again if symptoms appear.
The provided excerpt specifies testing prior to and at 12 weeks following initiation and any elevation of dose, but does not state retesting when symptoms appear.
Routine periodic liver function testing is no longer recommended unless patients show signs of liver trouble.
The supplied label excerpt does not describe discontinuation of routine periodic testing or condition-based testing phrasing.
Signs of liver trouble include unusual fatigue, dark urine, or upper-right abdominal pain.
No symptom list is provided in the supplied label excerpts.
Atorvastatin undergoes hepatic metabolism through CYP3A4.
CYP3A4 metabolism is not explicitly stated in the provided excerpts.
Overload of CYP3A4 can lead to toxic accumulation and enzyme elevation.
No such mechanistic statement is provided in the provided excerpts.
Existing liver impairment can lead to toxic accumulation and enzyme elevation.
The excerpt includes pharmacokinetics for hepatic impairment (Cmax/AUC), but does not connect this to “toxic accumulation and enzyme elevation” as stated.
Heavy alcohol use increases the risk of liver problems with atorvastatin.
No alcohol-related risk statement is present in the supplied excerpts.
Hepatitis C increases the risk of liver problems with atorvastatin.
No hepatitis C–specific risk statement is present in the supplied excerpts.
Other liver issues increase the risk of liver problems with atorvastatin.
No general statement about “other liver issues” increasing risk is present in the supplied excerpts.
Doctors often reduce the dose or switch to a different statin if liver tests come up abnormal.
The supplied excerpts do not state dosing changes/switching for abnormal liver tests.
Most enzyme elevations settle within weeks of stopping or lowering the drug.
No timeline for normalization after stopping or dose reduction is included in the supplied excerpts.
Severe liver injury is uncommon.
No label excerpt provided supports a statement about frequency of severe liver injury.
Severe liver injury requires immediate discontinuation and medical evaluation.
No label language in provided excerpts specifies immediate discontinuation for severe liver injury.
Simvastatin and lovastatin have higher rates of liver enzyme elevation than atorvastatin.
No comparative statements between statins are included in the supplied excerpts.
Rosuvastatin and pitavastatin appear to have lower risk profiles for liver enzyme elevation in comparative studies.
No comparative studies/risk profiles for other statins are included in the supplied excerpts.
Patients who react to one statin sometimes succeed with another.
No label excerpt provided supports patient switching/success after intolerance due to liver enzyme elevations.
Generic entry after patent expiry increased availability and lowered patient costs.
Not addressed in the provided FDA label excerpts (not a prescribing information claim).
Safety monitoring remains the same with generic atorvastatin.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
The label-supported liver testing recommendation is limited to “prior to and at 12 weeks following both the initiation of therapy and any elevation of dose,” but multiple user claims imply different testing timing (e.g., “if symptoms appear” and “no longer recommended routine periodic testing”).
Importance:
Moderate
No statements were made about contraindications beyond “active liver disease” (e.g., pregnancy/breastfeeding hypersensitivity) even though several safety-related claims were provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about liver monitoring and risk factors are not supported by the provided label excerpts (including symptom-based monitoring and cessation of routine periodic testing). Unsupported monitoring guidance could lead to inaccurate expectations about when testing is recommended.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Many claims are unsupported by the provided label excerpts, especially around liver injury specifics, monitoring frequency/timing, mechanism (CYP3A4 metabolism), risk modifiers (alcohol/hepatitis C), and comparative statin risks/case frequency.
Suggested Improvement
Restrict claims to the provided label-supported points: (1) active liver disease contraindication, (2) >3x ULN persistent elevation incidence of 0.7%, (3) liver function tests prior to and at 12 weeks after initiation and after dose increases, and (4) label-described adverse reaction/discontinuation frequencies. Remove or qualify unsupported mechanistic, epidemiologic, symptom-list, and comparative-statins statements unless matching label text is supplied.